Delving into Disitamab Vedotin: A Novel HER2 ADC

Time: 12:15 pm
day: Track C - Day 1 - AM


  • Disitamab vedotin is a HER2 ADC with an antibody designed to maximise drug delivery with higher affinity and internalisation rate as compared to trastuzumab in preclinical models
  • Highlighting DV’s encouraging monotherapy clinical data across a range of HER2 expressing solid tumours, and combination activity with anti-PD1 in urothelial cancer